Financial Performance - The net profit attributable to shareholders for 2022 was -14,648,702.48 yuan, while the parent company achieved a net profit of 4,555,356.15 yuan[6]. - The total distributable profit for 2022, after considering the beginning retained earnings of 188,295,557.58 yuan, was 192,850,913.73 yuan[6]. - The company plans not to distribute profits or increase capital reserves for the year 2022 due to the negative net profit situation[7]. - The company's operating revenue for 2022 was approximately ¥545.37 million, representing a year-over-year increase of 3.40% compared to ¥527.44 million in 2021[23]. - The net profit attributable to shareholders of the listed company improved to approximately -¥14.65 million in 2022, a 35.64% increase from -¥22.76 million in 2021[23]. - The net cash flow from operating activities was approximately ¥31.28 million, a significant recovery from -¥84.25 million in 2021[23]. - Total assets increased by 17.98% to approximately ¥1.46 billion in 2022, up from ¥1.24 billion in 2021[24]. - Basic earnings per share improved to -¥0.05 in 2022, a 37.50% increase from -¥0.08 in 2021[25]. - The weighted average return on equity increased by 1.31 percentage points to -2.30% in 2022, compared to -3.61% in 2021[25]. - The company reported a total of ¥4.62 million in non-recurring gains in 2022, compared to -¥0.64 million in 2021[30]. Operational Highlights - The company achieved operating revenue of CNY 545.37 million in 2022, an increase of CNY 17.93 million compared to the previous year[32]. - The net profit attributable to shareholders was CNY -14.65 million, an improvement of CNY 8.11 million year-on-year[32]. - R&D expenses amounted to CNY 27.73 million, a decrease of 9.46% from the previous year, focusing on new topical formulations and technology upgrades[34]. - The company holds 24 Class I medical device registrations and 12 Class II registrations, with all main products certified by the FDA and TUV[35]. - The company completed the construction of a new medical adhesive dressing production project, with actual investment exceeding the planned amount by 2.24%[39]. - The company has developed a new multi-size, thickened nitrile glove that is favored in the labor protection market[37]. - The company is focusing on expanding its product categories in the medical device industry, particularly in high-end protective gloves[36]. - The company has established itself as a leading manufacturer of medical devices, particularly in the wound care sector, with a strong market influence after over 30 years of operation[46]. Market and Industry Trends - The global medical device market is projected to reach USD 532.8 billion in 2022, with a CAGR of 5.6% until 2024[88]. - The demand for disposable protective gloves is driven by health and safety awareness, with significant market potential in emerging markets[89]. - The domestic medical dressing industry is experiencing increasing concentration, benefiting larger enterprises as the demand for healthcare quality and safety rises[44]. - The regulatory environment for medical devices has strengthened, with new policies implemented to ensure safety and quality, creating a favorable landscape for domestic manufacturers[43]. - The company is positioned to benefit from the national centralized procurement reforms, which are becoming a new norm in the medical device industry[117]. Research and Development - The company has established a research and development center in collaboration with Zhejiang University, focusing on transdermal drug delivery technology and tissue regeneration[60]. - The company has applied for three national invention patents, which have all been accepted, indicating progress in innovation[60]. - The company has increased its investment in protective gloves R&D and fixed assets, resulting in the formation of technical achievements in 2022[96]. - The company is exploring the development of more emergency series products for various scenarios, including home, traffic accidents, and natural disasters[95]. - The company is focused on optimizing the adhesive properties of medical tapes to reduce skin irritation and enhance environmental benefits[95]. Governance and Compliance - The company has established a sound corporate governance structure, complying with relevant laws and regulations to support sustainable development[135]. - The company emphasizes investor relations, utilizing multiple channels to engage with investors and protect their interests[140]. - The company adheres to strict information disclosure practices, ensuring timely and accurate communication with stakeholders[141]. - The company has implemented measures to manage risks associated with product liability and distributor management, which could impact sales[132][131]. - The company has not reported any significant differences in governance practices compared to regulatory requirements[142]. Financial Management and Strategy - The company aims to achieve an operating revenue of 700 million yuan and a profit of 30 million yuan in 2023, focusing on cost control and enhancing profitability[119]. - The company intends to enhance its financial management by reducing the debt-to-asset ratio and improving the efficiency of resource utilization[122]. - The company has a cash dividend policy that mandates a minimum of 25% of distributable profits to be distributed as cash dividends when conditions allow[165]. - The company has established a profit distribution plan that requires the board of directors to propose and draft based on the company's articles of association, profitability, and funding needs[166]. - The company has committed to rectifying the identified internal control deficiencies and has already received repayment of occupied funds from related parties[177]. Environmental and Social Responsibility - The company invested approximately 14.33 million yuan in environmental protection during the reporting period[180]. - The company operates 2 natural gas boilers with an annual consumption of 1.5 million cubic meters of natural gas, meeting emission standards for pollutants[182]. - The company has implemented measures to prevent noise pollution, ensuring compliance with the GB12348-2008 standards for industrial enterprises[183]. - The company made a total donation of 100,000 yuan for public welfare projects[186]. Shareholder and Management Information - The total shareholding of senior management at the beginning of the year was 12,829.13 million shares, which decreased to 12,823.13 million shares by the end of the year, reflecting a reduction of 6 million shares[144]. - The total pre-tax remuneration for senior management during the reporting period amounted to 251.42 million yuan[144]. - The company has a diverse management team with extensive experience across various sectors, enhancing its operational capabilities[146]. - The company is focused on maintaining stability in its shareholding structure while ensuring competitive remuneration for its executives[144].

Financial Performance - In 2021, the company's total revenue was ¥527,440,662.01, a decrease of 50.82% compared to ¥1,072,399,917.76 in 2020[21] - The net profit attributable to shareholders of the listed company for 2021 was -¥22,762,007.90, compared to a profit of ¥98,067,613.55 in 2020[21] - The net cash flow from operating activities was -¥84,252,019.54 in 2021, a significant decline from ¥154,122,592.63 in 2020[21] - The net assets attributable to shareholders of the listed company at the end of 2021 were ¥649,784,562.92, down 6.75% from ¥696,791,263.63 at the end of 2020[21] - The company reported a total revenue of 527.44 million yuan in 2021, a decrease of 54.50 million yuan compared to the previous year[30] - The net profit attributable to shareholders was -22.76 million yuan, a decrease of 120.83 million yuan year-on-year[30] - Basic earnings per share were -0.0778 yuan, down from 0.3426 yuan in 2020[23] - The weighted average return on equity decreased by 19.43 percentage points to -3.42%[23] - The gross profit margin for the industrial sector was 20.71%, down 13.16 percentage points from the previous year[69] - The company achieved operating revenue of 527.44 million yuan, a decrease of 54.50 million yuan compared to the same period last year[64] Corporate Governance - The company held 5 shareholder meetings and 12 board meetings to strengthen corporate governance[30] - A board and supervisory committee election was conducted in December 2021 to enhance governance structure[31] - The company emphasizes investor relations, maintaining communication with shareholders and stakeholders to protect their interests and enhance company value[146] - The company adheres to strict information disclosure practices, ensuring transparency and compliance with relevant regulations[147] - The company has implemented measures to manage insider information and maintain confidentiality, complying with regulatory requirements[148] - The company held 12 board meetings in the year, with 4 conducted in person and 8 combining in-person and communication methods[157] - The company has a clear mechanism for profit distribution decision-making, requiring board approval and shareholder meeting validation[173] - The company has established a robust internal control management system in compliance with regulatory requirements, enhancing decision-making efficiency and ensuring asset safety[178] Research and Development - The company invested CNY 30.623 million in R&D during the reporting period, a decrease of 9.83% compared to the previous year, focusing on new topical formulations and technology upgrades[33] - The company emphasizes technology research and development, focusing on transdermal drug delivery technology improvements and stem cell-based tissue regeneration[58] - The company has established a "New Transdermal Preparation Research Center" in collaboration with Zhejiang University to enhance its R&D capabilities[58] - The company added 4 invention patents and 9 utility model patents during the reporting period, totaling 11 invention patents and 33 utility models[94] - Major R&D projects included foam tape (2.42 million RMB, -26.36% YoY), breathable tape (2.58 million RMB, -43.73% YoY), and antibacterial masks (2.12 million RMB, -26.77% YoY)[103] Market Strategy and Expansion - The company is expanding its product line by adding a high-end medical glove production line, particularly focusing on nitrile gloves due to their superior protective qualities and market growth potential[34] - The company plans to continue expanding its market share and production capacity to lay a solid foundation for future domestic market growth[34] - The company is focusing on expanding its own brand products, particularly in first aid kits, protective gear, and nursing supplies, to enhance market presence[56] - The company is exploring market expansion opportunities and potential mergers and acquisitions to strengthen its competitive position[120] - The company plans to issue convertible bonds and has outlined a shareholder return plan for the next three years (2021-2023)[149] Environmental Responsibility - The company has implemented measures to prevent environmental pollution, including wastewater treatment and waste gas emission controls, meeting national standards[183] - The company uses clean energy sources, such as natural gas, for its operations, significantly reducing emissions[184] - The company has developed an emergency response plan for environmental incidents, enhancing its capability to manage potential environmental risks[185] - The company has committed to environmental responsibility, although specific measures for carbon emission reduction were not disclosed[187] Employee Management and Development - The company emphasizes the importance of employee training, focusing on legal regulations, professional skills, and management capabilities[170] - The company has a cash dividend policy that mandates a minimum of 25% of distributable profits to be distributed as cash dividends when conditions allow[172] - Employee wages have been steadily increased, with the company providing social insurance and housing funds for all employees[188] - The company has no outsourced labor arrangements, indicating a fully in-house workforce[171] Financial Management - The company is committed to enhancing shareholder value through strategic financial management and operational excellence[151] - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.4094 million yuan[153] - The company has implemented a stock buyback program, resulting in a reduction of 19.06 million shares[151] - The company is strengthening its financial management to lower the debt-to-asset ratio and improve operational efficiency[127] Risks and Challenges - The company reported a negative net profit for the first time, indicating potential challenges in its business strategy and market conditions[4] - The company faced risks related to product liability, litigation, and arbitration, which could potentially damage its reputation and operational capacity[135] - The COVID-19 pandemic has impacted the company's operations, including production, procurement, and market sales, with significant uncertainty regarding the future of its pandemic-related protective product lines[137]

Financial Performance - The company's operating revenue for 2020 reached ¥1,072,399,917.76, representing a 118.11% increase compared to ¥491,688,011.57 in 2019[20] - The net profit attributable to shareholders of the listed company was ¥98,067,613.55, a significant increase of 249.60% from ¥28,051,595.53 in the previous year[20] - The net profit after deducting non-recurring gains and losses was ¥86,701,465.59, up 275.58% from ¥23,084,715.39 in 2019[20] - The net cash flow from operating activities was ¥154,122,592.63, a 367.12% increase from ¥32,994,069.13 in 2019[21] - As of the end of 2020, the total assets amounted to ¥1,072,645,455.80, reflecting a 23.35% increase from ¥869,601,971.34 in 2019[21] - The net assets attributable to shareholders of the listed company were ¥696,791,263.63, which is a 23.51% increase compared to ¥564,157,337.40 at the end of 2019[21] - Basic earnings per share increased by 164.71% to CNY 0.45 in 2020 compared to CNY 0.17 in 2019[22] - The weighted average return on equity rose to 16.01%, an increase of 10.99 percentage points from 5.02% in 2019[22] - The company reported a net profit of CNY 9,432,898.99 for Q1 2020, reflecting a strong performance despite the pandemic[25] Dividend and Profit Distribution - The company plans to distribute a cash dividend of ¥1.5 per 10 shares, totaling approximately ¥33,777,000.00, and to increase the share capital by 3 shares for every 10 shares held[5] - The company has a cash dividend policy that mandates at least 25% of distributable profits to be distributed as cash dividends when conditions allow[144] - The company’s cash dividend distribution policy varies based on its development stage, with a minimum cash dividend of 80% for mature stages without major capital expenditures[144] - The company’s profit distribution plan for 2020 is subject to approval at the annual shareholders' meeting[148] - The company’s profit distribution proposal includes a capital reserve increase of 3 shares for every 10 shares held[147] - The company emphasizes the importance of maintaining a stable and continuous profit distribution policy to ensure reasonable returns for investors[143] Research and Development - R&D expenses amounted to 33.96 million yuan, reflecting a 52.30% increase year-on-year, focusing on new external preparations and transdermal drug delivery technology[61] - The company holds a total of 30 Class I medical device registrations and 14 Class II medical device registrations as of the end of the reporting period[62] - The company has obtained two national invention patents related to new external preparations for treating diabetic chronic ulcers and a new combination permeation agent[49] - The company is focusing on the R&D of hydrogel formulations and light-curing adhesives for transdermal drug delivery technology[99] - Major R&D projects included antibacterial medical bandages with an investment of RMB 3,771,980.69, accounting for 0.35% of revenue, showing a year-on-year increase of 37.31%[109] Market Position and Industry Overview - The company has established a strong market position in the medical device industry, leveraging nearly 30 years of operational experience and the cluster effect of the textile industry in the Yangtze River Delta[46] - The medical device market is expected to continue growing, driven by increased health awareness and government policies[92] - The company’s industry exhibits strong demand characteristics, showing resilience against macroeconomic fluctuations, indicating a lack of significant cyclicality[44] - The medical device industry in China remains fragmented, with many companies relying on traditional products and facing intense competition[125] Operational Efficiency and Production - The company has enhanced its production efficiency through automation and process improvements, leading to a reduction in production costs[61] - The production model is "sales-driven production," where production is organized based on customer demand, ensuring timely preparation of necessary raw materials for large clients[38] - The company is actively expanding its production capacity for various protective products while maintaining existing product sales[63] - The company primarily produces protective equipment, including daily protective masks, disposable medical masks, and surgical masks, catering to both the general public and healthcare professionals[36] Risks and Challenges - The company emphasizes that forward-looking statements do not constitute a commitment to investors and advises caution regarding potential risks[6] - The company faces risks from industry policy changes that could impact its operations and market competition[135] - The company is exposed to intensified market competition, particularly in the low-end medical device sector[136] - The company is at risk from fluctuations in foreign exchange rates, which could affect its export revenue and overall performance[138] Corporate Governance and Shareholder Rights - The company’s independent directors are involved in reviewing and providing opinions on the profit distribution proposals[145] - The controlling shareholder and actual controller, Li Ping, committed not to transfer or entrust the management of shares held directly or indirectly for 36 months from the date of the company's stock listing[152] - The company has committed to measures to ensure the filling of immediate returns that may be diluted by the initial public offering[156] - The company committed to optimizing investor returns and ensuring the protection of small investors' rights[157] Environmental and Social Responsibility - The company has established a social responsibility management system to enhance its sense of social responsibility[182] - The company utilizes clean production processes and has established measures to prevent water and air pollution, including the use of natural gas for boilers[187] - The company has a structured approach to waste management, ensuring hazardous waste is handled by qualified entities[188] - The company has established a long-term donation mechanism with local charity organizations to fulfill its social responsibilities[184] Legal Matters and Litigation - There are ongoing significant litigation matters involving equity transfer disputes, with updates disclosed in multiple announcements throughout the year[167] - The company has faced a lawsuit regarding a procurement contract for 35,000 masks, with a claim amounting to 514,150 RMB[168] - The company has incurred legal fees of 160,000 yuan related to ongoing litigation[172] - The company has requested the court to confirm the termination of a procurement contract and to order the return of 4,660,000 yuan in unpaid funds[172]

Financial Performance - The company's operating revenue for Q1 2023 was CNY 226,130,904.54, representing a year-on-year increase of 58.09%[5] - The net profit attributable to shareholders of the listed company was CNY 6,930,672.43, an increase of 3.03% compared to the same period last year[5] - The net profit for Q1 2023 was CNY 6,911,204.99, an increase from CNY 6,601,990.71 in Q1 2022, representing a growth of approximately 4.67%[18] - Operating profit for Q1 2023 was CNY 7,919,872.69, compared to CNY 7,439,759.53 in the same period last year, indicating an increase of about 6.45%[18] - Total revenue from operating activities reached CNY 296,570,290.27, significantly up from CNY 124,379,187.30 in Q1 2022, marking an increase of approximately 138.06%[19] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 20,595,515.00, with the increase attributed to higher sales and collections[8] - The cash flow from operating activities showed a net inflow of CNY 20,595,515.00, a recovery from a net outflow of CNY 25,084,420.24 in the previous year[20] - Cash and cash equivalents at the end of Q1 2023 totaled CNY 142,900,250.05, up from CNY 72,403,784.09 at the end of Q1 2022, indicating an increase of about 97.06%[20] - Cash and cash equivalents as of March 31, 2023, amounted to ¥147,126,389.89, compared to ¥127,818,267.43 at the end of 2022, representing a growth of 15.5%[14] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,490,102,502.58, up 2.26% from the end of the previous year[6] - Total liabilities increased to ¥856,041,522.47 in Q1 2023 from ¥835,750,892.20 in Q4 2022, showing a rise of 2.0%[15] - The company’s total assets impairment loss was CNY 2,108,279.06, compared to a gain of CNY 468,905.11 in Q1 2022, indicating a significant change in asset valuation[18] Shareholder Information - The company had a total of 15,707 common shareholders at the end of the reporting period[10] - Major shareholder Li Ping held 40.63% of the shares, with 74,188,784 shares pledged[10] Costs and Expenses - Total operating costs for Q1 2023 were ¥226,511,378.39, up from ¥137,739,528.05 in Q1 2022, reflecting an increase of 64.2%[16] - The company incurred financial expenses of CNY 2,391,515.19 in Q1 2023, down from CNY 4,299,454.46 in Q1 2022, representing a decrease of approximately 44.34%[18] - Research and development expenses for Q1 2023 were CNY 8,313,881.01, up from CNY 7,271,150.60 in Q1 2022, reflecting an increase of about 14.34%[18] Market and Growth Strategy - The increase in operating revenue was primarily driven by the sales of protective products[8] - The company is focusing on expanding its market presence and developing new products to enhance future growth prospects[16] Equity and Returns - Basic and diluted earnings per share were both CNY 0.024, reflecting a year-on-year increase of 4.35%[6] - The weighted average return on equity was 1.06%, a slight increase of 0.03% compared to the previous year[6] - The company reported a decrease of 1.04% in net profit after deducting non-recurring gains and losses, amounting to CNY 6,497,021.61[5] - The company reported a net loss for Q1 2023, with total costs exceeding total revenue, indicating challenges in profitability despite revenue growth[16]

证券代码：603880 证券简称：南卫股份 公告编号：2023-033 江苏南方卫材医药股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 05 月 05 日(星期五)至 05 月 11 日(星期四)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 info@nanfangmedical.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 江苏南方卫材医药股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度 经营成果、财务状况，公司计划于 2023 年 05 月 12 日上午 10:00-11:00 举行 2022 年度业绩暨现金分红说明会，就投资者关心的问题进行交流。 一、说明会类 ...

2022 年第三季度报告 证券代码：603880 证券简称：南卫股份 江苏南方卫材医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2022 年第三季度报告 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李平、主管会计工作负责人项琴华及会计机构负责人（会计主管人员）王亚华保 证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 减变动幅度 | 年初至报告期末 | 年初至报告期末 比上年同期增减 | | --- | --- | --- | --- | --- | | | | (%) | | 变动幅度(%) | | 营业收入 | 137,375,613.31 | -3.85 | 393,088,498.32 | ...

2022 年第三季度报告 证券代码：603880 证券简称：南卫股份 江苏南方卫材医药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人李平、主管会计工作负责人项琴华及会计机构负责人（会计主管人员）王亚华保 证季度报告中财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 2022 年第三季度报告 | 经营活动产生的现金 | 不适用 | 不适用 | 12,362,750.22 | 不适用 | | --- | --- | --- | --- | --- | | 流量净额 | | | | | | 基本每股收益（元/股） | 0.0031 | -74.37 | 0.03 | -40.00 | | 稀释每股收益（元/股） | 0.0031 | -74.23 | 0.03 | -40.00 ...

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 255,712,885.01, a decrease of 2.54% compared to CNY 262,370,249.21 in the same period last year[17]. - The net profit attributable to shareholders for the first half of 2022 was CNY 7,086,905.15, down 36.82% from CNY 11,216,493.04 in the previous year[17]. - Basic earnings per share decreased to CNY 0.024, down 36.84% from CNY 0.038 in the same period last year[18]. - The company reported a slight decrease of 0.97% in net profit after deducting non-recurring gains and losses, amounting to CNY 6,675,713.98 compared to CNY 6,741,322.81 in the previous year[17]. - The company achieved a revenue of 255.71 million yuan in the first half of 2022, a decrease of 2.54% year-on-year, and a net profit attributable to shareholders of 7.09 million yuan, down 36.82% year-on-year[46]. - The company reported a decrease in gross profit margin due to rising costs, with gross profit for the first half of 2022 at CNY 47,119,575.45 compared to CNY 59,773,554.49 in the previous year[134]. Cash Flow and Assets - The net cash flow from operating activities improved to CNY 21,192,688.41, compared to a negative cash flow of CNY -30,602,512.86 in the same period last year[17]. - The total assets increased by 11.52% to CNY 1,377,466,034.64 from CNY 1,235,190,728.96 at the end of the previous year[17]. - The company's cash and cash equivalents decreased to CNY 140,201,081.41 from CNY 152,815,444.27, reflecting a decline of approximately 8.5%[126]. - Accounts receivable increased to CNY 129,827,367.48 from CNY 107,324,765.46, representing a growth of about 20.9%[126]. - Inventory rose significantly to CNY 292,299,283.05 from CNY 216,813,857.94, marking an increase of approximately 34.8%[126]. - The company's total liabilities reached CNY 715,731,058.57, up from CNY 580,293,887.15, which is an increase of approximately 23.3%[128]. Market and Industry Position - The company is engaged in the production and sales of transdermal products, medical adhesive tapes, bandages, first aid kits, protective gear, and nursing products, positioning itself as a high-tech enterprise in the pharmaceutical manufacturing industry[27]. - The medical dressing industry in China is experiencing low market concentration, with many small regional enterprises competing primarily in the low-end market[26]. - The company anticipates that the demand for medical and health services will continue to rise, supported by increased government investment in public health infrastructure[26]. - The company is committed to expanding its market share in the medical dressing sector as industry concentration improves, favoring larger, well-managed enterprises[26]. - The company has established a strong market position as a leading medical device manufacturer in China, leveraging over 30 years of operational experience and a focus on ODM business models to meet domestic and international customer demands[39]. Research and Development - R&D expenses for the reporting period amounted to 14.85 million yuan, an increase of 6.74% compared to the same period last year, focusing on new external formulations and transdermal delivery technologies[47]. - The company emphasizes technology research and development, collaborating with Zhejiang University to advance transdermal drug delivery technologies and develop new transdermal products[40]. - The company is focusing on the development of new products, including transdermal products and first aid kits, to meet evolving market needs[28][30]. Risk Factors - The decrease in net profit was primarily due to a decline in operating revenue and an increase in operating costs, influenced by rising transportation and material costs due to the pandemic[19]. - The company has not disclosed any significant risks that could materially affect its operations during the reporting period[5]. - The company faces product liability risks that could damage its reputation and operational capabilities due to unforeseen factors such as litigation and arbitration[73]. - The company is facing challenges in maintaining profit margins due to increased competition in the market for disposable protective equipment[26]. - The company has not reported any significant integrity issues or large debts due during the reporting period[105]. Environmental and Compliance - The company has implemented effective environmental protection measures, including wastewater treatment and emissions control, complying with relevant standards[84]. - The company adheres strictly to national environmental laws and regulations, reflecting its commitment to sustainable practices[86]. - The company has developed an emergency response plan for environmental incidents, enhancing its capability to manage unexpected environmental events[86]. Shareholder and Governance - The company has not proposed any profit distribution or capital reserve transfer plans for the first half of 2022[80]. - The company plans to repurchase and cancel a total of 3.432 million restricted stocks due to unmet performance targets in 2021[81]. - The company’s major shareholders and management have committed to not selling their shares for six months after any stock buyback, ensuring stability in shareholding[90]. - The company will monitor and ensure compliance with the commitments made by its major shareholders and management to protect investor interests[96]. Legal and Disputes - The company has initiated legal proceedings against Changzhou Yierman Bedding Products Co., Ltd. for a contract dispute, claiming a refund of RMB 3.5807 million and a penalty of RMB 0.111 million[104]. - The company has recognized bad debts amounting to RMB 5.4510 million from a contract dispute with Beijing Sentai Weiye International Trade Co., Ltd.[103]. - The company is actively pursuing legal actions to recover amounts owed from various counterparties[103].

Financial Performance - The company's total revenue for 2021 was ¥527,440,662.01, representing a decrease of 50.82% compared to ¥1,072,399,917.76 in 2020[22] - The net profit attributable to shareholders for 2021 was -¥22,762,007.90, a significant decline from a profit of ¥98,067,613.55 in 2020[22] - The net cash flow from operating activities was -¥84,252,019.54, compared to ¥154,122,592.63 in the previous year, indicating a substantial decrease in operational cash generation[22] - The company's operating revenue for 2021 was CNY 527.44 million, a decrease of CNY 544.96 million compared to the previous year[31] - The net profit attributable to shareholders of the parent company was CNY -22.76 million, a decrease of CNY 120.83 million year-on-year[31] - Basic earnings per share were CNY -0.0778, down from CNY 0.3426 in 2020[24] - The weighted average return on equity was -3.42%, a decrease of 19.43 percentage points compared to 2020[24] - The company reported a gross margin of 20.71%, down 13.16 percentage points from the previous year[70] Shareholder and Governance - The company plans not to distribute profits or increase capital reserves for 2021 due to the negative net profit situation[4] - The company has a three-year shareholder return plan in place, which will be considered in future profit distribution decisions[4] - The company held 5 shareholder meetings and 12 board meetings during the reporting period to strengthen corporate governance[31] - The company emphasizes investor relations, maintaining communication with shareholders and stakeholders to protect their interests and enhance corporate value[147] - The company adheres to strict information disclosure practices, ensuring transparency and compliance with relevant regulations[148] - The company has a cash dividend policy that stipulates a minimum of 25% of distributable profits must be distributed as cash dividends when conditions allow[173] Risk Management - The company has not identified any significant risks that could materially affect its operations during the reporting period[7] - The company is facing risks from intensified market competition and potential changes in industry regulations that could impact its operations[132][133] - The company faces risks from changes in the overseas market environment, which may adversely affect its operations due to political, economic, and trade policy factors[134] - Fluctuations in exchange rates could impact the company's performance, particularly as export revenues are primarily settled in USD and EUR, with potential adverse effects if the RMB experiences significant volatility[135] Research and Development - The company invested CNY 30.623 million in R&D during the reporting period, a decrease of 9.83% compared to the previous year, focusing on new topical formulations and transdermal drug delivery technologies[34] - The company emphasizes technology research and development as a key competitive advantage, focusing on transdermal drug delivery technology improvements and stem cell-based tissue regeneration[59] - The company has established a "New Transdermal Preparation Research Center" in collaboration with Zhejiang University to enhance its R&D capabilities[59] - The company added 4 invention patents and 9 utility model patents during the reporting period, totaling 11 invention patents and 33 utility models[95] Product Development and Market Strategy - The company plans to expand its product line by adding a high-end medical glove production line, particularly focusing on nitrile gloves, which have shown rapid growth in the market[35] - The company is focusing on expanding its nitrile glove production capacity, which is expected to enhance market competitiveness[89] - The company is committed to improving its product offerings in the medical supplies sector, including various types of adhesive bandages and medical gloves[92] - The company is exploring the development of solvent-free medical adhesives and improving transdermal drug delivery technologies[97] Operational Efficiency - The company has a procurement model based on "sales-driven ordering," ensuring raw materials are sourced according to production orders[54] - The production model is "sales-driven production," allowing the company to adapt to customer demands and maintain service quality for large clients[55] - The company has a management team with extensive experience and a structured management system covering all operational aspects[62] - The company is committed to maintaining product quality and reducing production costs through improved procurement and supplier management[34] Environmental and Social Responsibility - The company has implemented measures to prevent water pollution, including a rainwater drainage system and proper disposal of hazardous waste[184] - The company actively engages in clean production practices and regularly maintains its environmental facilities to comply with national regulations[186] - The company has established a social responsibility management system, emphasizing a people-oriented approach and continuous improvement[188] - Employee wages have been steadily increased, with the company providing social insurance and housing funds for all employees[188] Financial Management - The company has successfully reduced its debt levels, improving its financial stability and credit rating[152] - The company is committed to optimizing its resource allocation and improving financial management to reduce costs and enhance profitability[128] - The company is seeking long-term partnerships with strategic suppliers and sales channels to build a stable production and sales integration[129] Strategic Partnerships and Acquisitions - The company is expanding its business into the cosmetics sector through a partnership with Shanghai Meilianni Cosmetics Co., transferring all related business qualifications and assets[198] - South Health Co. acquired 60% equity of Meilinni Bio from Shanghai Meilinni Cosmetics Co., with a transfer price of 12.8 million yuan based on financial status and future performance forecasts[200]

Financial Performance - The company's operating revenue for Q1 2022 was CNY 143,042,582.58, representing a year-on-year increase of 0.95%[5] - The net profit attributable to shareholders decreased by 26.31% to CNY 6,726,764.33 compared to the same period last year[5] - Basic and diluted earnings per share both fell by 25.81% to CNY 0.023[5] - The net profit for Q1 2022 was CNY 6,601,990.71, a decrease of 26.5% compared to CNY 8,980,922.60 in Q1 2021[17] - The total comprehensive income for Q1 2022 was CNY 6,601,990.71, down from CNY 8,980,922.60 in Q1 2021[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at CNY -25,084,420.24, a decline of 54.38% year-on-year[5] - The operating cash flow net amount was -CNY 25,084,420.24, an improvement from -CNY 54,987,217.80 in Q1 2021[20] - The company's cash and cash equivalents decreased to CNY 105,888,454.29 from CNY 152,815,444.27 as of December 31, 2021, a decline of 30.67%[12] - The cash and cash equivalents at the end of the period were CNY 72,403,784.09, a decrease from CNY 253,432,324.99 at the end of Q1 2021[20] Assets and Liabilities - Total assets at the end of the reporting period increased by 7.63% to CNY 1,329,431,755.29 compared to the end of the previous year[6] - Total liabilities increased to CNY 674,228,104.44 from CNY 580,293,887.15, reflecting a rise of 16.16%[14] - Non-current assets totaled CNY 743,926,568.53, compared to CNY 647,299,487.79, indicating an increase of 14.91%[13] - Short-term borrowings increased significantly to CNY 443,614,595.56 from CNY 352,230,315.56, a rise of 26.00%[13] Shareholder Information - The company has 18,186 common shareholders as of the reporting period[8] - The top shareholder, Li Ping, holds 43.4% of the shares, amounting to 127,025,048 shares, with a portion pledged[9] - The equity attributable to shareholders increased slightly by 0.15% to CNY 650,745,369.69[6] Operational Costs and Expenses - Total operating costs for Q1 2022 were CNY 137,739,528.05, up from CNY 133,269,629.14 in Q1 2021, reflecting an increase of 3.52%[16] - The company faced increased costs due to rising raw material prices, higher depreciation, and increased financial expenses, impacting profitability[7] - Research and development expenses were CNY 7,271,150.60, slightly down from CNY 7,577,590.98 in the previous year[17] - The company incurred interest expenses of CNY 3,922,079.33, significantly higher than CNY 1,582,133.34 in the previous year[17] Investment Activities - The total investment activities cash outflow was CNY 109,982,766.05, compared to CNY 61,100,480.31 in the previous year, indicating increased investment activity[20] - The financing activities generated a net cash flow of CNY 83,654,932.16, up from CNY 56,009,567.78 in Q1 2021[20] Market and Product Development - The company did not report any new product developments or market expansion strategies during this quarter[11]